The Coretec Group Inc. (CRTG) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	12-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'TDCP	'
Entity Common Stock, Shares Outstanding	'	353,684,566
Entity Registrant Name	'3DICON CORP	'
Entity Central Index Key	'0001375195	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$9,446	$70,769
Prepaid expenses	22,916	13,919
Total current assets	32,362	84,688
Deferred debt costs, net	12,727	25,455
Deposits-other	2,315	2,315
Total Assets	47,404	112,458
Current liabilities:	'	'
Convertible notes and debentures payable	497,224	612,744
Warrant exercise advances	148,706	185,671
Accounts payable	221,019	140,410
Accrued salaries	38,959	1,713
Accrued interest on debentures	24,301	22,751
Total current liabilities	930,209	963,289
Total Liabilities	930,209	963,289
Common stock subject to put rights and call right, 1,685,714 shares	485,649	485,649
Stockholders' deficiency:	'	'
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 385,000 and 195,000 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	77	39
Common stock $0.0002 par, 1,500,000,000 shares authorized; 330,519,206 and 248,191,444 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	66,104	49,638
Additional paid-in capital	18,992,740	18,618,714
Deficit accumulated during development stage	-20,427,375	-20,004,871
Total Stockholders' Deficiency	-1,368,454	-1,336,480
Total Liabilities and Stockholders' Deficiency	$47,404	$112,458

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common stock subject to put rights and call right, shares	1,685,714	1,685,714
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	385,000	195,000
Preferred Stock, Shares Outstanding	385,000	195,000
Common stock, par	$0.00	$0.00
Common stock, shares authorized	1,500,000,000	1,500,000,000
Common stock, shares issued	330,519,206	248,191,444
Common stock, shares outstanding	330,519,206	248,191,444

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		159 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Income:	'	'	'
License fee	$0	$0	$25,000
Sales	10,000	1,500	55,297
Grant income	28,748	0	354,136
Total income	38,748	1,500	434,433
Expenses:	'	'	'
Research and development	60,336	103,604	5,110,995
General and administrative	378,109	263,972	15,049,512
Interest	22,807	20,267	701,301
Total expenses	461,252	387,843	20,861,808
Net loss	($422,504)	($386,343)	($20,427,375)
Loss per share:	'	'	'
Basic and diluted	($0.00)	($0.01)	'
Weighted average shares outstanding, Basic and diluted	286,990,688	51,179,718	'

STATEMENTS_OF_CHANGES_IN_STOCK

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

159 Months Ended

Jan. 23, 2014

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Mar. 31, 2014

Beginning Balance

($1,336,480)

($1,336,480)

($1,468,849)

($1,468,849)

($1,246,529)

($1,626,230)

($1,792,157)

($2,211,746)

($921,198)

($881,748)

($386,897)

($369,457)

$20,929

$112,433

$162,972

$221,212

$221,212

Accrue compensation earned but unrecorded

'

'

'

'

'

'

'

'

'

'

'

'

'

-90,000

-60,000

-60,000

'

Warrants and options exercised

'

94,830

'

420,740

871,052

756,840

'

'

362,694

'

'

'

'

'

'

'

'

Debentures converted

'

45,700

'

568,828

39,779

703,546

279,191

483,004

965,309

1,677,183

150,000

'

'

'

'

'

'

Escrowed shares cancelled

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation

'

'

'

'

354,040

285,600

418,112

'

654,199

1,274,666

'

'

'

'

'

'

'

Options exercised and escrowed shares

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

0

'

30,000

'

'

'

'

'

87,864

33,800

'

'

'

'

'

'

Retrospective adjustment for reverse common stock split

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Warrants converted to purchase common stock (in shares)

190,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants converted to purchase common stock

'

'

'

'

'

'

'

'

'

463,920

568,500

'

'

'

'

'

'

Par value $0.0001 to $0.0002

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Stock warrants exercised

'

'

'

'

'

'

518,000

382,590

'

'

'

174,000

61,000

'

'

'

'

Net loss for the period

'

-422,504

-386,343

-1,482,049

-2,101,702

-2,320,469

-1,523,737

-1,566,835

-3,611,550

-3,928,996

-1,469,888

-592,811

-617,875

-51,851

-267,887

-259,221

-20,427,375

Ending Balance

'

-1,368,454

'

-1,336,480

-1,468,849

-1,246,529

-1,626,230

-1,792,157

-2,211,746

-921,198

-881,748

-386,897

-369,457

20,929

112,433

162,972

-1,368,454

Stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

45,000

'

295,350

246,100

355,205

232,886

538,354

313,800

155,426

206,537

26,371

76,489

15,347

129,448

188,131

'

Stock issued for cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

190,000

'

268,000

'

'

10,000

202,000

25,000

192,136

16,200

72,300

28,808

35,000

147,900

72,850

'

Warrants issued to purchase common stock at $.025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

62,300

18,900

'

'

'

'

Warrants issued to purchase common stock at $.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

140,400

42,292

'

'

'

'

Additional founders shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Stock issued to settle liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

15,000

'

31,500

366,364

556,027

214,414

'

'

'

'

100,000

'

'

'

'

'

Stock issued for interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

2,047

42,952

17,061

43,309

'

38,351

'

'

'

'

'

'

'

Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debentures converted

'

'

'

'

'

'

'

323,662

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

13,505

'

'

'

'

'

'

'

'

'

Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance (in shares)

195,000

195,000

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Beginning Balance

39

39

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Accrue compensation earned but unrecorded

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

'

Warrants and options exercised (in shares)

'

0

'

0

0

0

'

0

0

'

'

'

'

'

'

'

'

Warrants and options exercised

'

0

'

0

0

0

'

'

0

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

0

'

'

'

0

'

0

0

0

0

0

'

Debentures converted (in shares)

'

0

'

0

0

0

0

0

0

0

0

'

'

'

'

'

'

Debentures converted

'

0

'

0

0

0

0

0

0

0

0

'

'

'

'

'

'

Escrowed shares cancelled (In Shares)

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Escrowed shares cancelled

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation

'

'

'

'

0

0

0

'

0

0

'

'

'

'

'

'

'

Options exercised and escrowed shares (in shares)

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

Options exercised and escrowed shares

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

0

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Retrospective adjustment for reverse common stock split (in Shares)

'

'

'

'

'

0

'

'

'

'

'

'

'

0

'

'

'

Retrospective adjustment for reverse common stock split

'

'

'

'

'

0

'

'

'

'

'

'

'

0

'

'

'

Warrants converted to purchase common stock (in shares)

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Warrants converted to purchase common stock

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Par value $0.0001 to $0.0002

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Stock warrants exercised (in shares)

'

'

'

'

'

'

0

'

'

'

'

0

0

'

'

'

'

Stock warrants exercised

'

'

'

'

'

'

0

0

'

'

'

0

0

'

'

'

'

Net loss for the period

'

0

'

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending Balance (in shares)

'

385,000

'

195,000

0

0

0

0

0

0

0

0

0

0

0

0

385,000

Ending Balance

'

77

'

39

0

0

0

0

0

0

0

0

0

0

0

0

77

Preferred Stock | Stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

0

'

0

0

'

0

0

0

'

0

'

'

'

'

'

'

Stock issued

'

0

'

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Preferred Stock | Stock issued for cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

190,000

'

195,000

'

'

0

0

0

0

0

0

0

0

0

0

'

Stock issued

'

38

'

39

'

'

0

0

0

0

0

0

0

0

0

0

'

Preferred Stock | Warrants issued to purchase common stock at $.025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Preferred Stock | Warrants issued to purchase common stock at $.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Preferred Stock | Additional founders shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Preferred Stock | Stock issued to settle liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

0

'

0

0

0

0

'

'

'

'

0

'

'

'

'

'

Stock issued

'

0

'

0

0

0

0

'

'

'

'

0

'

'

'

'

'

Preferred Stock | Stock issued for interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

0

0

0

0

'

0

'

'

'

'

'

'

'

Stock issued

'

'

'

'

0

0

0

0

'

0

'

'

'

'

'

'

'

Preferred Stock | Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Debentures converted

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance (in shares)

248,191,414

248,191,414

45,934,839

45,934,839

32,928,654

757,539,307

343,690,812

157,515,766

127,125,232

98,336,656

73,947,656

56,737,656

5,241,656

35,689,560

31,133,560

27,723,750

27,723,750

Beginning Balance

49,638

49,638

9,187

9,187

6,586

151,508

68,738

31,503

25,425

19,666

14,789

11,347

1,048

35,690

31,134

27,724

27,724

Accrue compensation earned but unrecorded

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

'

Warrants and options exercised (in shares)

'

249

'

1,103

2,285

12,308,915

'

35,100

1,347,261

'

'

'

'

'

'

'

'

Warrants and options exercised

'

1

'

1

1

2,462

'

'

269

'

'

'

'

'

'

'

'

Debentures converted (in shares)

'

65,634,126

'

175,264,242

9,884,674

252,267,600

255,650,977

77,451,141

15,257,163

17,215,200

3,000,000

'

'

'

'

'

'

Debentures converted

'

13,127

'

35,053

1,976

50,453

51,130

15,490

3,052

3,442

600

'

'

'

'

'

'

Escrowed shares cancelled (In Shares)

'

'

'

'

'

-4,310,446

'

'

'

'

'

'

'

'

'

'

'

Escrowed shares cancelled

'

'

'

'

'

-862

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation

'

'

'

'

0

0

0

'

0

0

'

'

'

'

'

'

'

Options exercised and escrowed shares (in shares)

'

'

'

'

'

'

'

'

8,671,460

222,707

'

'

'

'

'

'

'

Options exercised and escrowed shares

'

'

'

'

'

'

'

'

1,734

45

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

0

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Retrospective adjustment for reverse common stock split (in Shares)

'

'

'

'

'

-1,119,574,221

'

'

'

'

'

'

'

-47,174,904

'

'

'

Retrospective adjustment for reverse common stock split

'

'

'

'

'

-223,915

'

'

'

'

'

'

'

0

'

'

'

Warrants converted to purchase common stock (in shares)

'

'

'

'

'

'

'

'

'

8,585,956

16,489,000

'

'

'

'

'

'

Warrants converted to purchase common stock

'

'

'

'

'

'

'

'

'

1,717

3,297

'

'

'

'

'

'

Par value $0.0001 to $0.0002

'

'

'

'

'

'

'

'

'

'

'

'

'

-51,369

'

'

'

Stock warrants exercised (in shares)

'

'

'

'

'

'

47,523

'

'

'

'

5,260,000

2,100,000

'

'

'

'

Stock warrants exercised

'

'

'

'

'

'

9

7

'

'

'

1,052

420

'

'

'

'

Net loss for the period

'

0

'

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending Balance (in shares)

'

330,519,206

'

248,191,414

45,934,839

32,928,654

757,539,307

343,690,812

157,515,766

127,125,232

98,336,656

73,947,656

56,737,656

5,241,656

35,689,560

31,133,560

330,519,206

Ending Balance

'

66,104

'

49,638

9,187

6,586

151,508

68,738

31,503

25,425

19,666

14,789

11,347

1,048

35,690

31,134

66,104

Common Stock | Stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

9,376,344

'

25,892,479

2,248,640

30,072,595

97,684,416

68,506,130

4,598,973

817,727

4,700,000

5,850,000

24,036,000

15,347,000

3,077,000

2,681,310

'

Stock issued

'

1,875

'

5,178

450

6,015

19,538

13,701

920

164

940

1,170

4,807

15,347

3,077

2,681

'

Common Stock | Stock issued for cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

0

'

0

'

'

5,714,286

20,607,841

515,677

1,188,960

200,000

1,100,000

360,000

1,380,000

1,479,000

728,500

'

Stock issued

'

0

'

0

'

'

1,143

4,122

103

238

40

220

72

1,380

1,479

729

'

Common Stock | Warrants issued to purchase common stock at $.025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Common Stock | Warrants issued to purchase common stock at $.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Common Stock | Additional founders shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

Stock issued

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

Common Stock | Stock issued to settle liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

7,317,073

'

1,098,751

869,510

97,530,393

48,657,897

'

'

'

'

5,000,000

'

'

'

'

'

Stock issued

'

1,463

'

219

173

19,506

9,732

'

'

'

'

1,000

'

'

'

'

'

Common Stock | Stock issued for interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

1,076

7,094,511

6,093,396

8,310,128

'

767,026

'

'

'

'

'

'

'

Stock issued

'

'

'

'

1

1,419

1,218

1,662

'

153

'

'

'

'

'

'

'

Common Stock | Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued (in shares)

'

'

'

'

'

'

'

11,264,706

'

'

'

'

'

'

'

'

'

Debentures converted

'

'

'

'

'

'

'

2,253

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Additional Paid-In Capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

18,618,714

18,618,714

17,044,786

17,044,786

15,168,005

12,322,913

10,716,019

8,766,830

6,451,906

2,568,119

1,597,959

1,026,030

808,840

723,851

451,059

193,488

193,488

Accrue compensation earned but unrecorded

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

'

Warrants and options exercised

'

94,829

'

420,739

871,051

754,378

'

'

362,425

'

'

'

'

'

'

'

'

Debentures converted

'

32,573

'

533,775

37,803

653,093

228,061

467,514

962,257

1,673,741

149,400

'

'

'

'

'

'

Escrowed shares cancelled

'

'

'

'

'

862

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation

'

'

'

'

354,040

285,600

418,112

'

654,199

1,274,666

'

'

'

'

'

'

'

Options exercised and escrowed shares

'

'

'

'

'

'

'

'

-1,734

-45

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

0

'

30,000

'

'

'

'

'

87,864

33,800

'

'

'

'

'

'

Retrospective adjustment for reverse common stock split

'

'

'

'

'

223,915

'

'

'

'

'

'

'

0

'

'

'

Warrants converted to purchase common stock

'

'

'

'

'

'

'

'

'

462,203

565,203

'

'

'

'

'

'

Par value $0.0001 to $0.0002

'

'

'

'

'

'

'

'

'

'

'

'

'

51,369

'

'

'

Stock warrants exercised

'

'

'

'

'

'

517,991

382,583

'

'

'

172,948

60,580

'

'

'

'

Net loss for the period

'

0

'

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Ending Balance

'

18,992,740

'

18,618,714

17,044,786

15,168,005

12,322,913

10,716,019

8,766,830

6,451,906

2,568,119

1,597,959

1,026,030

808,840

723,851

451,059

18,992,740

Additional Paid-In Capital | Stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

43,125

'

290,172

245,650

349,190

213,348

524,653

312,880

155,262

205,597

25,201

71,682

0

126,371

185,450

'

Additional Paid-In Capital | Stock issued for cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

189,962

'

267,961

'

'

8,857

197,878

24,897

191,898

16,160

72,080

28,736

33,620

146,421

72,121

'

Additional Paid-In Capital | Warrants issued to purchase common stock at $.025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

62,300

18,900

'

'

'

'

Additional Paid-In Capital | Warrants issued to purchase common stock at $.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

140,400

42,292

'

'

'

'

Additional Paid-In Capital | Additional founders shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

'

'

'

'

'

'

'

'

-5,000

'

'

'

'

Additional Paid-In Capital | Stock issued to settle liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

13,537

'

31,281

366,191

536,521

204,682

'

'

'

'

99,000

'

'

'

'

'

Additional Paid-In Capital | Stock issued for interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

2,046

41,533

15,843

41,647

'

38,198

'

'

'

'

'

'

'

Additional Paid-In Capital | Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debentures converted

'

'

'

'

'

'

'

321,409

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

13,505

'

'

'

'

'

'

'

'

'

Deficit Accumulated During the Development Stage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

-20,004,871

-20,004,871

-18,522,822

-18,522,822

-16,421,120

-14,100,651

-12,576,914

-11,010,079

-7,398,529

-3,469,533

-1,999,645

-1,406,834

-788,959

-647,108

-319,221

0

0

Accrue compensation earned but unrecorded

'

'

'

'

'

'

'

'

'

'

'

'

'

-90,000

-60,000

-60,000

'

Warrants and options exercised

'

0

'

0

0

0

'

'

0

'

'

'

'

'

'

'

'

Debentures converted

'

0

'

0

0

0

0

0

0

0

0

'

'

'

'

'

'

Escrowed shares cancelled

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation

'

'

'

'

0

0

0

'

0

0

'

'

'

'

'

'

'

Options exercised and escrowed shares

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

0

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Retrospective adjustment for reverse common stock split

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Warrants converted to purchase common stock

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Par value $0.0001 to $0.0002

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Stock warrants exercised

'

'

'

'

'

'

0

0

'

'

'

0

0

'

'

'

'

Net loss for the period

'

-422,504

'

-1,482,049

-2,101,702

-2,320,469

-1,523,737

-1,566,835

-3,611,550

-3,928,996

-1,469,888

-592,811

-617,875

-51,851

-267,887

-259,221

'

Ending Balance

'

-20,427,375

'

-20,004,871

-18,522,822

-16,421,120

-14,100,651

-12,576,914

-11,010,079

-7,398,529

-3,469,533

-1,999,645

-1,406,834

-788,959

-647,108

-319,221

-20,427,375

Deficit Accumulated During the Development Stage | Stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

0

'

0

0

0

0

0

0

0

0

0

0

0

0

0

'

Deficit Accumulated During the Development Stage | Stock issued for cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

0

'

0

'

'

0

0

0

0

0

0

0

0

0

0

'

Deficit Accumulated During the Development Stage | Warrants issued to purchase common stock at $.025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Deficit Accumulated During the Development Stage | Warrants issued to purchase common stock at $.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and options exercised

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Deficit Accumulated During the Development Stage | Additional founders shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Deficit Accumulated During the Development Stage | Stock issued to settle liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

0

'

0

0

0

0

'

'

'

'

0

'

'

'

'

'

Deficit Accumulated During the Development Stage | Stock issued for interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

0

0

0

0

'

0

'

'

'

'

'

'

'

Deficit Accumulated During the Development Stage | Accounts payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debentures converted

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

STATEMENTS_OF_CHANGES_IN_STOCK1

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2005	Dec. 31, 2004	Dec. 31, 2005	Dec. 31, 2004	Dec. 31, 2003	Dec. 31, 2003
	Warrants issued to purchase common stock at $.025	Warrants issued to purchase common stock at $.025	Warrants issued to purchase common stock at $.05	Warrants issued to purchase common stock at $.05	Maximum	Minimum
Purchase common stock	$0.03	$0.03	$0.05	$0.05	'	'
Price change of par value	'	'	'	'	$0.00	$0.00

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		159 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash Flows from Operating Activities	'	'	'
Net loss	($422,504)	($386,343)	($20,427,375)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Options issued for services	0	0	2,986,618
Stock issued for services	45,000	0	2,824,444
Stock issued for interest	0	0	143,719
Book value of assets retired	0	0	6,529
Amortization of deferred debt costs	33,588	16,260	344,269
Depreciation	0	1,541	37,000
Impairment of assets	0	0	292,202
Change in:	'	'	'
Accounts receivable	0	13,028	0
Prepaid expenses and other assets	-8,997	5,444	-273,631
Accounts payable and accrued liabilities	134,405	96,255	2,689,490
Net cash used in operating activities	-218,508	-253,815	-11,376,735
Cash Flows from Investing Activities	'	'	'
Purchase of office furniture and equipment	0	0	-43,529
Net cash used in investing activities	0	0	-43,529
Cash Flows from Financing Activities	'	'	'
Proceeds from stock and warrant sales, exercise of warrants and warrant exercise advances	247,865	209,950	6,495,241
Proceeds from issuance of debentures and notes	25,000	90,400	5,170,659
Cash paid on debentures	-115,680	0	-236,200
Net cash provided by financing activities	157,185	300,350	11,429,700
Net change in cash	-61,323	46,535	9,436
Cash, beginning of period	70,769	1,350	10
Cash, end of period	9,446	47,885	9,446
Non-Cash Investing and Financing Activities	'	'	'
Conversion of debentures to common stock (net)	45,700	54,317	4,911,989
Cash paid for interest	397	2,432	325,238
Stock issued to satisfy payables	15,000	0	2,400,117
Debenture issued to satisfy payable	0	0	352,547
Stock issued subject to put rights and call right to satisfy payables	$0	$0	$485,649

Uncertainties_and_Use_of_Estim

Uncertainties and Use of Estimates	3 Months Ended
	Mar. 31, 2014
Uncertainties and Use Of Estimates [Abstract]	'
Uncertainties and Use of Estimates	'
	Note 1 – Uncertainties and Use of Estimates
	Basis of Presentation
	The accompanying financial statements of 3DIcon Corporation (the “Company”) have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company's year-end audited financial statements and related footnotes included in the previously filed 10-K. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company as of March 31, 2014, and the statements of its operations for the three months ended March 31, 2014 and March 31, 2013, and the period from inception (January 1, 2001) to March 31, 2014, and cash flows for the three-month periods ended March 31, 2014 and 2013, and the period from inception (January 1, 2001) to March 31, 2014, have been included. The results of operations for interim periods may not be indicative of the results which may be realized for the full year.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.
	Revenue Recognition
	Revenues from software license fees are accounted for in accordance with Accounting Standards Codification (“ASC”) 985-605, “Software Revenue Recognition”. The Company recognizes sales revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.
	Grant revenue is recognized when earned.
	Recent Accounting Pronouncements
	Based on management's assessment, no new accounting standards, if adopted, would have a material impact on the accompanying financial statements.
	Uncertainties
	The accompanying financial statements have been prepared on a going concern basis. The Company is in the development stage and has insufficient revenue and capital commitments to fund the development of its planned product and to pay operating expenses.
	The Company has realized a cumulative net loss of $20,427,375 for the period from inception (January 1, 2001) to March 31, 2014, and a net loss of $422,504 and $386,343 for the three-months ended March 31, 2014 and 2013, respectively.
	The ability of the Company to continue as a going concern depends on the successful completion of the Company's capital raising efforts to fund the development of its planned products. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Management plans to fund the future operations of the Company with existing cash of $9,446, grants and investor funding.  Under the terms of the Golden State 4.75% Convertible Debenture due on December 31, 2014, Golden State is obligated to submit conversion notices in an amount such that Golden State receives 1% of the outstanding shares of the Company every calendar quarter for a period of one year. In connection with each conversion, Golden State is expected to simultaneously exercise a percentage of warrants equal to the percentage of the principal being converted.  The warrants are exercisable at $381.50 per share.  The number of warrants exercisable is subject to certain beneficial ownership limitations contained in the 4.75% Convertible Debenture (“the Beneficial Ownership Limitations”).  The Beneficial Ownership Limitations prevent Golden State from converting on the 4.75% Convertible Debenture or exercising warrants if such conversion or exercise would cause Golden State’s holdings to exceed 9.99% of the Company’s issued and outstanding common stock.  Subject to the Beneficial Ownership Limitations and provided that Golden State is able to sell the shares under Rule 144, Golden State is required to convert $85.71 of the 4.75% Convertible Debenture and exercise 857 warrants per month.  Based upon the current stock price, the issued and outstanding shares as of March 31, 2014 and ignoring the impact of the Beneficial Ownership Limitations, the Company may receive up to $327,000 per month in funding from Golden State as a result of warrant exercises. Due to the Beneficial Ownership Limitations, the Company received $13,175 in advances from Golden State during the three-month period ended March 31, 2014. Such advances are recorded within warrant exercise advances on the balance sheets when received.
	On July 2, 2013, the Company was awarded a $300,000 grant in the 2013 Oklahoma Applied Research Support competition sponsored by the Oklahoma Center for the Advancement of Science and Technology (“OCAST”). The grant will be used to support the development of the Company’s first Product Platform, which will be the basis for a family of products based on the Company’s CSpace® volumetric 3D display technology (see Note 3).
	Joint Development Agreement with Schott Defense
	As part of the Company’s federal funding strategy, the Company intends to effectively compete by forming interdisciplinary teams with potential strategic partners (large and small), academic and commercial laboratories, and systems integrators providing integrated data visualization solutions. The first of these partnerships was reached in March 2014 when the Company signed a Joint Development Agreement with Schott Defense, a federally focused subsidiary of Schott North America.
	Additionally, the Company is continuing to pursue financing through private offering of debt or common stock.

Sponsored_Research_Agreement_S

Sponsored Research Agreement ("SRA") Common Stock Subject to Put Right and Call Right	3 Months Ended
	Mar. 31, 2014
Sponsored Research Agreement Common Stock Subject To Put Rights and Call Right [Abstract]	'
Sponsored Research Agreement ("SRA") Common Stock Subject to Put Right and Call Right	'
	Note 2 – Sponsored Research Agreement ("SRA") Common Stock Subject to Put Rights and Call Right
	Since April 20, 2002, the Company has entered into a number of SRA’s with the University of Oklahoma (“OU”) as follows:
	Phase I: “Pilot Study to Investigate Digital Holography,” April 20, 2004. The Company paid OU $14,116.
	Phase II: “Investigation of 3-Dimensional Display Technologies,” April 15, 2005, as amended. The Company paid OU $528,843.
	Phase III: “3-Dimensional Display Development.” The Company made partial payment to OU by issuing 121,849 post-split equivalent shares (4,264,707 pre-split shares) with a market price of $290,000 on October 14, 2008 and final payment on December 1, 2010 in the amount of $525,481 of which $40,481 was in cash and 1,685,714 post-split equivalent shares (59,000,000 pre-split) of Company stock (the “Shares”). The Shares are subject to an OU ‘put’ right and a 3Dicon ‘call’ right.
	OU “Put” Rights on the Shares
	First “put” period: December 1, 2012 to November 30, 2013. If the shares (held plus previously sold) are valued at less than $100,000 then OU can “put” one-tenth of the shares for $50,000 plus accrued interest retro-active to December 1, 2012 less the value of sold shares. OU currently holds 1,807,563 post-split shares with a market value of less than $100,000. Under the terms of put rights, the put rights could be exercised by OU and the Company would be obligated to pay OU $50,000.
	Second “put” period: December 1, 2013 to November 30, 2014. If the shares (held & previously sold) are valued at less than $970,000 than OU can “put” the remaining shares for $485,000 plus accrued interest retro-active to December 1, 2012 less the value of shares previously sold or redeemed during the first “put.”
	3DIcon “Call” rights on the shares
	Commencing December 1, 2012, the Company shall have the right to “call” the shares for an amount equal to $970,000 less the amount (if any) of prior shares by OU including amounts “put” to 3DIcon.
	The Company has presented the shares outside of deficit in the mezzanine section of the balance sheets, as the Agreement includes put rights, which are not solely within the control of the Company.
	The SRA also amended the previously existing agreements between the Company and OU such that all intellectual property, including all inventions and or discoveries, patentable or un-patentable, developed before July 28, 2008 by OU under the SRA is owned by OU. All intellectual property, including all inventions and/or discoveries, patentable or un-patentable, developed jointly by the Company and OU at any time is jointly owned by the Company and OU. Finally, all intellectual property developed by the Company after July 28, 2008, including all inventions and or discoveries, patentable or un-patentable, is owned by the Company.

OCAST_Grant

OCAST Grant	3 Months Ended
	Mar. 31, 2014
Oklahoma Center For Advancement Of Science and Technology Grant [Abstract]	'
OCAST Grant	'
	Note 3 – OCAST Grant
	In July 2013, the Company was awarded a two year grant from OCAST. This is the second $300,000 grant received from OCAST. The first grant was completed in August 2012. This matching grant is for a total of $300,000 commencing September 1, 2013.  The funds will be used to support the development of the Company’s first Product Platform, which will be the basis for a family of products based on the Company’s CSpace® volumetric 3D display technology.

Debentures_and_Notes_Payable

Debentures and Notes Payable	3 Months Ended
	Mar. 31, 2014
Debentures and Notes Payable [Abstract]	'
Debentures and Notes Payable	'
	Note 4 – Debentures and Notes Payable
	Debentures payable consist of the following:
		March 31,		December 31,
		2014		2013
	Senior Convertible Debentures:
	10% Convertible debentures to Directors due June 2014	$	30,000	$	30,000
	10% Convertible debenture due June 2014		29,007		29,007
	4.75% Convertible debenture due December 2014		68,935		69,805
	5.0% Convertible notes due July 2014 (net of $16,482 and $19,115 OID)		115,532		123,590
	15% Convertible bridge notes due 2014 (net of $11,250 and $23,500 OID)		193,750		181,500
	Settlement Agreement 3(a)(10)		-		118,842
	10% Convertible bridge note to Director due December 2014		60,000		60,000
	Total Debentures		497,224		612,744
	Less - Current Maturities		-497,224		-612,744
	Long-term Debentures	$	-	$	-
	10% Convertible Director Debentures
	On June 24, 2013, the Company issued to Victor Keen and Martin Keating, Directors of the Company (“Directors”), 10% convertible debentures in a principal amount of $15,000 each, due June 26, 2014. The Directors may elect to convert all or any portion of the outstanding principal amount of the debentures at an exercise price of $0.01 per share. Provided that the debentures are paid in full on or before the maturity date, no interest shall accrue on the unpaid balance of the principal amount. In the event that the debentures are not paid in full on or before the maturity date, interest shall accrue on the unpaid outstanding balance of the principal amount of the debentures from June 26, 2013, until paid, at the fixed rate of ten percent (10%) per annum.
	10% Convertible Debenture Due Newton, O'Connor, Turner & Ketchum
	On December 20, 2012, the Company issued to Newton, O'Connor, Turner & Ketchum (“NOTK”) a 10% convertible debenture in a principal amount of $29,007, initially due September 30, 2013 and extended to June 30, 2014.  NOTK may elect to convert all or any portion of the outstanding principal amount of the debenture at an exercise price of $0.02534 per share. The Company was indebted to NOTK for legal services performed for the Company and reimbursement of expenses in rendition of those services for the period ended December 31, 2012. The debenture was issued in settlement of the indebtedness.
	4.75% Convertible Debenture due December 31, 2014
	On November 3, 2006, the Company issued to Golden State a 4.75% convertible debenture in a principal amount of $100,000, due in 2014, and warrants to buy 28,571 shares of the common stock at an exercise price of $381.50 per share. In connection with each conversion, Golden State is expected to simultaneously exercise a percentage of warrants equal to the percentage of the principal being converted. During 2013, Golden State converted $3,860 of the $100,000 debenture into 37,651,544 shares of common stock, exercised warrants to purchase 1,103 shares of common stock at $381.50 per share based on the formula in the convertible debenture. Additionally Golden State advanced $671,810 against future exercises of warrants of which $420,740 was applied to the exercise of warrants leaving $185,671 of unapplied advances at December 31, 2013. During 2014, Golden State converted $870 of the $100,000 debenture into 32,423,426 shares of common stock, exercised warrants to purchase 249 shares of common stock at $381.50 per share based on the formula in the convertible debenture. Additionally Golden State advanced $13,175 against future exercises of warrants of which $50,140 was applied to the exercise of warrants leaving $148,706 of unapplied advances at March 31, 2014.
	The conversion price for the 4.75% $100,000 convertible debenture is the lesser of (i) $140; or (ii) 80% of the average of the five lowest volume weighted average prices during the twenty (20) trading days prior to the conversion. If Golden State elects to convert a portion of the debenture and, on the day that the election is made, the volume weighted average price is below $0.70, the Company shall have the right to prepay that portion of the debenture that Golden State elected to convert, plus any accrued and unpaid interest, at 135% of such amount.
	5% Convertible Bridge Notes
	On June 6, 2012 and August 1, 2012, the Company issued and sold convertible promissory notes (the “5% Notes") in aggregate principal amount of $415,000 to JMJ Financial (“JMJ”).  The 5% Notes includes a $40,000 original issue discount (the “OID”) that will be prorated based on the advances actually paid to the Company. During 2012, JMJ advanced $150,000 on the 5% Notes and earned $14,000 OID. During 2013, JMJ advanced an additional $120,000 on the 5% Notes and earned $32,205 OID and accrued interest.  During 2013, JMJ converted $203,700 of the 5% Notes into 31,854,924 shares of common stock at an average of $0.00639 per share based on the formula in the 5% Notes. During 2014, JMJ advanced an additional $25,000 on the 5% Notes and earned $5,975 OID and accrued interest.  During 2014, JMJ converted $41,667 of the 5% Notes into 17,400,000 shares of common stock at an average of $0.00239 per share based on the formula in the 5% Notes. In addition to the OID, the 5% Notes provides for a one-time interest charge of 5% to be applied to the principal sum advanced.  Pursuant to the terms of 5% Notes, JMJ may, at its election, convert all or a part of the $275,000 note and the $140,000 note into shares of the Company's common stock at a conversion rate equal to the lesser of (i) $0.15 and $0.35, respectively or (ii) 70% of the lowest trade price during the twenty-five trading days prior to JMJ’s election to convert. If the Company repays the 5% Notes on or before ninety days from the date it was issued, the interest rate will be zero percent. If the Company does not repay the 5% Notes on or before ninety days from the date it was issued, a one-time interest charge of 5% shall be applied to the principal. The Company did not repay the 5% Notes within the ninety day period and $20,750 of interest has been expensed. The principal of the 5% Notes is due one year from the date of each of the principal amounts advanced.
	The 5% Notes were subject to a Mandatory Registration Agreement (the “Registration Agreement”) whereby no later than August 31, 2012, the Company agreed to file, at its own expense, an amendment (the “Amendment”) to the S-1 Registration Statement (the “Registration Statement”) the Company filed with the SEC on July 3, 2012, to include in such Amendment 4,750,000 shares of common stock issuable under the 5% Notes. The Company agreed, thereafter, to use its best efforts to cause such Registration Statement to become effective as soon as possible after such filing but in no event later than one hundred and twenty (120) days from the date of the Registration Agreement. Since the Company failed to get the Registration Statement declared effective within the 120 days of the date of the Registration Agreement, a penalty/liquidated damages of $25,000 was added to the balance of the 5% Notes.
	10% Convertible Bridge Note to Director
	On September 11, 2012, the Company issued and sold to Victor Keen, a Director and an accredited investor a Convertible Bridge Note (the “Keen Bridge Note”) in the principal amount of $60,000. The sale of the Keen Bridge Note in the principal of $60,000 included a $10,000 OID. Accordingly, the Company received $50,000 gross proceeds. The Keen Bridge Note matured 90 days from the date of issuance and, other than the OID, the Keen Bridge Note do not carry interest. However, in the event the Keen Bridge Note is not paid on maturity, all past due amounts will accrue interest at 15% per annum. Upon maturity of the Keen Bridge Note, the holders of the Keen Bridge Note may elect to convert all or any portion of the outstanding principal amount of the Keen Bridge Note into (i) securities sold pursuant to an effective registration statement at the applicable offering price; or (ii) shares of common stock at a conversion price equal to the lesser of 100% of the Volume Weighted Average Price (VWAP), as reported for the 5 trading days prior to (a) the date of issuance of the Keen Bridge Note, (b) the maturity date of the Keen Bridge Note, or (c) the first closing date of the securities sold pursuant an effective registration statement.
	On January 26, 2013, the Company entered into an amendment agreement (the “Keen Amendment”) with Victor F. Keen, the holder of the Keen Bridge Note in the principal amount of $60,000 issued by the Company on September 10, 2012.
	The Keen Bridge Note matured on or about December 10, 2012, on which date all past due amounts of the Keen Bridge Note began accruing interest at 15% per annum. Pursuant to the Keen Amendment, Mr. Keen agreed to extend the maturity date of the Keen Bridge Note from December 10, 2012 to April 30, 2013 and to waive any and all defaults, default interest and Liquidated Damages then due to Mr. Keen.
	On July 30, 2013 (the “Amendment Date”), the Company entered into a second amendment agreement (the “Second Keen Amendment”) with Victor Keen, a Director on the Board of Directors of the Company, to amend the Keen Bridge note.
	Pursuant to the Second Keen Amendment, Mr. Keen agreed to extend the maturity of the Note from May 15, 2013 to August 31, 2013 (the “New Maturity Date”) and to waive, if any, existing or prior defaults under the Keen Bridge Note or the Keen SPA and the Company agreed to (i) amend the conversion provision to allow for conversions based on a conversion price calculated on the Amendment Date or the New Maturity Date; and (ii) to include an interest rate equal to 10% per annum, payable on the New Maturity Date, as amended, which accrual shall commence on December 10, 2012.
	On September 30, 2013 (the “Amendment Date”), the Company entered into a third amendment agreement (the “Third Keen Amendment”) with Victor Keen, a Director on the Board of Directors of the Company, to amend the Keen Bridge note.
	Pursuant to the Third Keen Amendment, Mr. Keen agreed to extend the maturity of the Note from August 31, 2013 to December 31, 2013 (the “New Maturity Date”) and to waive, if any, existing or prior defaults under the Keen Bridge Note or the Keen SPA.
	On January 27, 2014 (the “Amendment Date”), the Company entered into a fourth amendment agreement (the “Fourth Keen Amendment”) with Victor Keen, a Director on the Board of Directors of the Company, to amend the Keen Bridge note.
	Pursuant to the Fourth Keen Amendment, Mr. Keen agreed to extend the maturity of the Note from December 31, 2013 to December 31, 2014 (the “New Maturity Date”) and to waive, if any, existing or prior defaults under the Keen Bridge Note or the Keen SPA.
	15% Convertible bridge notes due 2014
	On October 1, 2013 (the “Date of Issuance”), 3DIcon Corporation issued and sold to an accredited investor a Senior Convertible Note (the “Senior Note”) in the principal amount of $205,000 and a warrant to purchase 300,000 shares of the Company’s common stock at an exercise price equal to 110% of the closing bid price on September 30, 2013 (the “October 2013 Warrant”). The Senior Note included a $30,750 OID. Accordingly, the Company received $174,250 gross proceeds from which the Company paid legal and documentation fees of $22,500 and placement agent fees of $15,682.
	The Senior Note matures on July 1, 2014 and does not carry interest. However, in the event the Senior Note is not paid on maturity, all past due amounts will accrue interest at 15% per annum. At any time subsequent to six months following the Date of Issuance, the Senior Note holder may elect to convert all or any portion of the outstanding principal amount of the Senior Note into shares of Common Stock at a conversion price equal to the lesser of 100% of the Volume Weighted Average Price (VWAP), as reported for the 5 trading days prior to the Date of Issuance or 80% of the average VWAP during the 5 days prior to the date the holder delivers a conversion notice to the Company.
	The estimated fair value of the warrants for common stock issued of $2,130 was determined using the Black-Scholes option pricing model. The expected dividend yield of zero is based on the average annual dividend yield as of the issue date. Expected volatility of 173.64% is based on the historical volatility of our stock. The risk-free interest rate of 1.39% is based on the U.S. Treasury Constant Maturity rate for five years as of the issue date. The expected life of five years of the warrant is based on historical exercise behavior and expected future experience.
	The October 2013 Warrant is exercisable at any time on or after March 31, 2014 and on or prior to the close of business on March 31, 2019. At the election of the October 2013 Warrant holder, the October 2013 Warrant may be exercised using a cashless exercise method.
	Settlement Agreement
	On July 26, 2013, the Circuit Court in the 12th Judicial Circuit in and for Sarasota County, Florida (the “Court”), entered an Order Granting Approval of Settlement Agreement (the “Order”) approving, among other things, the fairness of the terms and conditions of an exchange pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, in accordance with a settlement agreement (the “Settlement Agreement”) between the Company and IBC Funds, LLC, a Nevada limited liability company (“IBC”), in the matter entitled IBC Funds, LLC v. 3DIcon Corporation, Case No. 2013 CA 5705 NC (the “Action”). IBC commenced the Action against the Company on July 19, 2013 to recover an aggregate of $197,631 of past-due accounts payable of the Company, which IBC had purchased from certain vendors of the Company pursuant to the terms of separate claim purchase agreements between IBC and each of such vendors (the “Assigned Accounts”), plus fees and costs (the “Claim”). The Assigned Accounts relate to certain research, technical, development, accounting and legal services.  The Order provides for the full and final settlement of the Claim and the Action. The Settlement Agreement became effective and binding upon the Company and IBC upon execution of the Order by the Court on July 26, 2013.
	Pursuant to the terms of the Settlement Agreement approved by the Order, on July 26, 2013, the Company issued 650,000 shares of Common Stock as a settlement fee and agreed to issue, in one or more tranches as necessary, that number of shares equal to $197,631 upon conversion to Common Stock at a conversion rate equal to 65% of the lowest closing bid price of the Common Stock during the ten trading days prior to the date the conversion is requested by IBC minus $0.002.  During 2013, IBC converted $78,789 of the note into 53,720,000 shares of common stock at an average of $0.0015 per share based on the formula in the note.
	On January 22, 2014 the Company entered into a Mutual Release (the “Release”) with IBC Funds, LLC pursuant to which each party would release the other party from any and all obligations pursuant to that certain court-approved Settlement Agreement dated as of July 26, 2013, as described in the Company’s Current Report on Form 8-K filed on July 31, 2013.
	In consideration for the Release, IBC will accept and the Company will remit to IBC: (i) a cash payment of $190,000, (ii) an issuance of 9,000,000 shares of the Company’s common stock, pursuant to the terms of the Settlement Agreement under the December 18, 2013 Conversion Notice, and (iii) an issuance of 6,810,811 shares of the Company’s common stock, pursuant to the terms of the Settlement Agreement under the January 17, 2014 Conversion Notice (together, the “Consideration”). Pursuant to the Release, IBC has agreed that the Consideration shall be accepted as satisfaction in full of the payments due pursuant to the Settlement Agreement.
	On January 23, 2014, the Company and IBC filed a Stipulation of Dismissal with Prejudice with the Circuit Court in the 12th Judicial Circuit in and for Sarasota County, Florida.

Common_Stock_and_PaidIn_Capita

Common Stock and Paid-In Capital	3 Months Ended
	Mar. 31, 2014
Common Stock, Including Additional Paid In Capital, Net Of Discount [Abstract]	'
Common Stock and Paid-In Capital	'
	Note 5 – Common Stock and Paid-In Capital
	Registration Statement on Form S-1
	Pursuant to a Registration Statement on Form S-1 and the prospectus therein, filed on July 3, 2012, and amendment thereto, the Registration Statement was declared effective on February 13, 2013.
	Warrants issued
	As of December 31, 2013, NOTK has warrants outstanding to purchase 125,098 shares of common stock at a price of $3.15 per share that expire on May 22, 2014 and, warrants to purchase 96,024 shares of common stock at a price of $3.15 per share that expire on June 1, 2015.  Golden State has warrants outstanding to purchase 19,942 shares of common stock at a price of $381.50 per share which expire December 31, 2014. Global Capital has warrants outstanding to purchase 300,000 shares of common stock at a price of $0.0032 per shares which expire on March 31, 2019.  Additionally, in connection with the preferred stock issuance, there are 9,750,000 warrants outstanding to purchase common shares at $0.0055 per share, which expire December 31, 2017, and 9,500,000 warrants outstanding that were issued to Victor Keen, the CEO and Director of the Company, which expire on January 17, 2018.
	Common stock and options issued for services and liabilities
	During the three-month period ended March 31, 2014, shares of common stock totaling 9,376,344 were issued for consulting services for which the Company recognized $45,000 of expense.  Additionally, during the period ending March 31, 2014, shares totaling 7,317,073 were issued to consultants for previous services provided to the Company for which the accounts payable liability was reduced by $15,000.
	Employment Agreement - On March 19, 2012 the Company announced that Sidney Aroesty would resign as CEO and join the Board of Directors. Effective April 15, 2013, Mr. Aroesty resigned as a member of the Board of Directors.
	Employment Agreement - On November 1, 2013, Mark Willner resigned as CEO of 3DIcon Corporation in order to allow Victor F. Keen to take over in his place as the Company’s newly appointed Interim CEO.
	Mr. Willner’s resignation was not a result of any dispute with the Company. Furthermore, Mr. Willner will assume a strategic consulting role with the Company, focusing his efforts on the commercialization of and business development of the Company’s patented 3D display technology, CSpace®.
	Mr. Keen, formerly Co-Chairman of the Company’s Board of Directors, will remain a member of the Board while John M. O’Connor, also a former Co-Chairman, was newly elected as the sole Chairman of the Board. Mr. Keen has been a member of the Board since November 2007.
	Employment Agreement - On March 16, 2012, the Company entered into a one (1) year Agreement for At-Will Employment with Assignment of Inventions (“Employment Agreement”) with George Melnik, pursuant to which Dr. Melnik began serving as the Company’s Senior Technical Advisor, effective immediately. Under the terms of the Employment Agreement, Dr. Melnik is entitled to an annual base salary of $144,000, and, at the discretion of the Company’s Board of Directors, performance-based bonuses and/or salary increases. Pursuant to the Employment Agreement, the Company granted Dr. Melnik five-year stock options to purchase 28,571 shares at a price equal to the average price of the five day period prior to March 16, 2012 which was $0.35 (the “Strike Price”). Furthermore, since Dr. Melnik remained employed by the Company at the end of each quarter ending June 30, 2012, September 30, 2012 and December 31, 2012, he received additional stock options to purchase 28,571 shares at the Strike Price. In addition, since the Company achieved certain quarterly business objectives, Dr. Melnik received, at the end of each such quarterly period, a further grant of stock options to purchase 28,571 shares at the Strike Price. The estimated fair value of each of the 28,571 block of options, valued at $9,420, was determined using the Black-Scholes option pricing model and was charged to operations in March 2012, June 2012, September 2012 and December 2012. The expected dividend yield of $-0- is based on the average annual dividend yield as of the grant date. Expected volatility of 163% is based on the historical volatility of the stock since July 25, 2007, the day the Company began trading on the Over-The-Counter Bulletin Board. The risk-free interest rate of 1.87% is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option of five years is based on historical exercise behavior and expected future experience.
	The Employment Agreement may be terminated with or without reason by either the Company or Dr. Melnik and at any time, upon sixty (60) days written notice. The terms of the Employment Agreement will remain effective for one (1) year and will automatically renew, subject to the same termination rights. Upon termination, the Company will pay any base pay, bonus and benefits that have been earned and are due as of the date of the termination.
	Employment Agreement - On January 28, 2013, the Board of Directors of the Company appointed Ronald Robinson to serve as the Company’s Chief Financial Officer. Accordingly, the Company decided not to renew its agreement with Christopher T. Dunstan pursuant to which Mr. Dunstan served as the Company’s Interim Chief Financial Officer. The Company’s appointment of Mr. Robinson and decision not to renew its agreement with Mr. Dunstan was not as a result of any disagreement between the Company and Mr. Dunstan.
	On April 11, 2013, the Company completed the sale of two options, each to purchase 10,000,000 shares of the Company’s common stock (the “Option Agreements”) to two accredited investors. One of the accredited investors was Victor Keen, a director on the Board of Directors of the Company. Each of the Option Agreements provide for the option to purchase up to 10,000,000 shares of restricted common stock at a purchase price of $0.01 per share. The holders of the Option Agreements may exercise the option to purchase common stock on a cashless basis for a period of five years. Furthermore, the holders of the Option Agreements were granted “piggyback” registration rights for the inclusion, on a subsequent registration statement, the shares of common stock underlying the Option Agreements. The gross proceeds to the Company for the sale of both Option Agreements were $100,000.
	Private Placement
	On December 9, 2013 and December 11, 2013 the Company closed on $195,000 in a private placement (the “Private Placement”) contemplated by a Securities Purchase Agreement (the “Securities Purchase Agreement”), dated December 9, 2013, pursuant to which the Company sold 195,000 Units (as defined below) to accredited investors (each, an “Investor” and collectively, the “Investors”), one of whom was Victor Keen, the Company’s Chief Executive Officer and a member of the board of directors of the Company. Accordingly, at the closings, the Company issued (i) 195,000 shares of its newly designated Series A Convertible Preferred Stock (the “Series A Preferred”), and (ii) warrants (“Warrants”) to purchase an aggregate of 9,750,000 shares of Common Stock for gross proceed of $195,000.
	January 23, 2014, the Company sold to Victor Keen, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, 190,000 Units for a purchase price of $190,000, as part of the Private Placement (as defined therein) disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2013. Pursuant to such Private Placement, the Company has now received aggregate proceeds equal to $385,000. Such Private Placement is now closed.
	Under the terms of the Securities Purchase Agreement, the Company sold units (“Units”) consisting of: (i) one share of Series A Convertible Preferred Stock and (ii) Warrants to purchase fifty (50) shares of Common Stock. The purchase price of each Unit was $1.00. The total purchase price of the securities sold in the Private Placement was $385,000.
	The terms of the Series A Convertible Preferred Stock and Warrants are as follows:
	Series A Convertible Preferred Stock
	A total of 500,000 shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) have been authorized for issuance under the Certificate of Designation of Preferences, Rights and Limitation of Series A Convertible Preferred Stock of 3DIcon Corporation (the “Certificate of Designation”), which Certificate of Designation was filed with the Secretary of State of the State of Oklahoma on December 11, 2013. The shares of Series A Preferred Stock have a par value of $0.0002 per share (the “Stated Value”), and shall receive a dividend of 6% of their Stated Value per annum. Under the Certificate of Designation, the holders of the Series A Preferred Stock have the following rights, preferences and privileges:
	The Series A Preferred Stock may, at the option of the Investor, be converted at any time after the first anniversary of the issuance of the Series A Preferred Stock or from time to time thereafter into 50,000,000 shares of Common Stock that Such Investor is entitled to in proportion to the 500,000 shares of Series A Preferred so designated in the Certificate of Designation.
	The Series A Preferred Stock will automatically be converted into Common Stock anytime the 5 day average VWAP of the Company’s Common Stock prior to such conversion is equal to $0.05 or more. Such mandatory conversion would be converted by the same method described above for discretionary conversions.
	Except as otherwise required by law, the holders of shares of Series A Preferred Stock shall not have voting rights or powers.
	In the event of any (i) liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or ii) sale, merger, consolidation, reorganization or other transaction that results in a change of control of the Company, each holder of a share of Series A Preferred shall be entitled to receive, subject to prior preferences and other rights of any class or series of stock of the Company senior to the Series A Preferred, but prior and in preference to any distribution of any of the assets or surplus funds of the Company to holders of Common Stock, or any other class or series of stock of the Company junior to the Series A Preferred, an amount equal to the Stated Value plus accrued and unpaid dividends (as adjusted for any stock dividends, combinations or splits with respect to such shares) (the “Preference Amount”). After such payment has been made to the holders of Series A Preferred of the full Preference Amount to which such holders shall be entitled, the remaining net assets of the Company available for distribution, if any, shall be distributed pro rata among the holders of Common Stock. In the event the funds or assets legally available for distribution to the holders of Series A Preferred are insufficient to pay the Preference Amount, then all funds or assets available for distribution to the holders of capital stock shall be paid to the holders of Series A Preferred pro rata based on the full Preference Amount to which they are entitled.
	The Company may not declare, pay or set aside any dividends on shares of any class or series of capital stock of the Company (other than dividends on shares of Common Stock payable in shares of Common Stock) unless the holders of the Series A Preferred Stock shall first receive, or simultaneously receive, a dividend on each outstanding share of Series A Preferred in an amount equal to the dividend per share that such holders would have received had they converted their shares of Series A Preferred into shares of Common Stock immediately prior to the record date for the declaration of the Common Stock dividend in an amount equal to the average VWAP during the 5 trading days prior to the date such dividend is due.
	Warrants
	Each Unit under the Securities Purchase Agreement consists of Warrants entitling the Investor to purchase fifty (50) shares of Common Stock for each share of Series A Preferred purchased by such Investor in the Private Placement, at an initial exercise price per share of $0.0055. The exercise price and number of shares of Common Stock issuable under the Warrants are subject to adjustments for stock dividends, splits, combinations and similar events. On or after the first anniversary of the issuance of the Warrants and prior to close of business on fourth anniversary of the issuance of the Warrants and may be exercised at any time upon the election of the holder, provided however, that an Investor may at any given time convert only up to that number of shares of Common Stock so that, upon conversion, the aggregate beneficial ownership of the Company’s Common Stock (calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of such Investor and all persons affiliated with such Investor, is not more than 4.99% of the Company’s Common Stock then outstanding (subject to adjustment up to 9.99% at the Investor’s discretion upon 61 days’ prior notice).
	The $27,000 estimated fair value of warrants for common stock issued in 2013 was determined using the Black-Scholes option pricing model. The expected dividend yield of $0 is based on the average annual dividend yield at the date issued. Expected volatility of 178% is based on the historical volatility of the stock. The risk-free interest rate of 1.38% is based on the U.S. Treasury Constant Maturity rates as of the issue date. The expected life of the warrants of four years is based on historical exercise behavior and expected future experience.
	The $34,926 estimated fair value of warrants for common stock issued in 2014 was determined using the Black-Scholes option pricing model. The expected dividend yield of $0 is based on the average annual dividend yield at the date issued. Expected volatility of 180% is based on the historical volatility of the stock. The risk-free interest rate of 1.64% is based on the U.S. Treasury Constant Maturity rates as of the issue date. The expected life of the warrants of four years is based on historical exercise behavior and expected future experience.
	Transaction Documents Series A Convertible Preferred Stock
	The Securities Purchase Agreement, the Warrants and Certificate of Designation contain ordinary and customary provisions for agreements of this nature, such as representations, warranties, covenants, and indemnification obligations, as applicable. The foregoing descriptions of the Securities Purchase Agreement and the Warrants do not purport to describe all of the terms and provisions thereof and are qualified in their entirety by reference. The Securities Purchase Agreement and the form of Warrant are filed as Exhibits 4.1 and 10.1, respectively, to the Current Report on Form 8-K filed on December 13, 2013.
	The following summary reflects warrant and option activity for the three-month period ended March 31, 2014:
		Attached		Golden State
		Warrants		Warrants		Options
	Outstanding December 31, 2013		10,271,122		19,942		23,030,274
	Granted/purchased		9,500,000		-		-
	Exercised		-		-249		-
	Cancelled		-		-		-
	Outstanding March 31, 2014		19,771,122		19,693		23,030,274
	Stock options are valued at the date of award, which does not precede the approval date, and compensation cost is recognized in the period the options are granted. Stock options generally become exercisable on the date of grant and expire based on the terms of each grant.
	The estimated fair value of options for common stock granted was determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience.

Incentive_Stock_Plan

Incentive Stock Plan	3 Months Ended
	Mar. 31, 2014
Incentive Stock Plan [Abstract]	'
Incentive Stock Plan	'
	Note 6 – Incentive Stock Plan
	In April 2012, the Company established the 3DIcon Corporation 2012 Equity Incentive Plan (the "2012 EIP"). The total number of shares of stock which may be purchased or granted directly by options, stock awards or restricted stock purchase offers, or purchased indirectly through exercise of options granted under the 2012 EIP shall not exceed five million (5,000,000) post-split shares.  The shares are included in a registration statement filed May 3, 2012. Post-split shares totaling 2,827,537 and 2,172,463 were issued from the 2012 EIP during 2013 and 2012 respectively, for services rendered and to satisfy accounts payable to the Company. There are currently -0- shares available for issuance under the 2012 EIP.
	In June 2013, the Company established the 3DIcon Corporation 2013 Equity Incentive Plan (the "2013 EIP"). The total number of shares of stock which may be purchased or granted directly by options, stock awards or restricted stock purchase offers, or purchased indirectly through exercise of options granted under the 2013 EIP shall not exceed twenty million (20,000,000) post-split shares.  The shares are included in a registration statement filed June 10, 2013. Post-split shares totaling 20,000,000 were issued from the 2013 EIP during 2013 for services rendered. There are currently -0- shares available for issuance under the 2013 EIP.
	In March 2014, the Company established the 3DIcon Corporation 2014 Equity Incentive Plan (the “2014 EIP”). The total number of shares of stock which may be purchased or granted directly by options, stock awards or restricted stock purchase offers, or purchased indirectly through exercise of options granted under the 2014 EIP shall not exceed fifty million (50,000,000) post-split shares. The shares are included in a registration statement filed March, 2014. Post-split shares totaling 12,046,093 were issued from the 2014 EIP during 2014 for services rendered. There are currently 37,563,907 shares available for issuance under the 2014 EIP.

Office_Lease

Office Lease	3 Months Ended
	Mar. 31, 2014
Office Lease [Abstract]	'
Office Lease	'
	Note 7 – Office Lease
	The Company signed an Office Lease Agreement (the “Lease Agreement”) on April 24, 2008. The Lease Agreement commenced on June 1, 2008 and expired June 1, 2011. On March 8, 2011 the Lease Agreement was amended (amendment 1) to extend the expiration date to May 31, 2012.  On July 24, 2012 the Lease Agreement was amended (amendment 2) to extend the expiration date to July 31, 2015.    The minimum future lease payments to be paid annually under the three-year non-cancellable amended operating lease for office space are as follows:
	2014		17,000
	2015		13,000
	Total	$	30,000

Related_Party_Transaction

Related Party Transaction	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transaction	'
	Note 8 – Related Party Transaction
	3DIcon has engaged the law firm of Newton, O’Connor, Turner & Ketchum as its outside corporate counsel since 2005. John O’Connor, a director of 3DIcon, is the Chairman of Newton, O’Connor, Turner & Ketchum.   During the three-month ending March 31, 2014 and  March 31,  2013, the Company incurred legal fees to Newton, O’Connor, Turner & Ketchum in the amount of $1,940 and $8,203, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 9 – Subsequent Events
	Common stock issued for services and liabilities
	Subsequent to March 31, 2014, Golden State converted $850 of the 4.75% convertible debenture into 7,982,953 shares of common stock at $0.00011 per share and exercised 243 warrants at $381.50 per share for $92,650 and advanced $46,325 for future exercise of warrants under the terms of the securities purchase agreements.
	Subsequent to March 31, 2014, JMJ converted $22,050 of the convertible promissory note into 9,000,000 shares of common stock at $0.0025 under the terms of the securities purchase agreements.
	Subsequent to March 31, 2014, shares of common stock totaling 4,496,450 were issued for consulting services for which the Company recognized $9,267 of expense.

Uncertainties_and_Use_of_Estim1

Uncertainties and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2014
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements of 3DIcon Corporation (the “Company”) have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company's year-end audited financial statements and related footnotes included in the previously filed 10-K. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company as of March 31, 2014, and the statements of its operations for the three months ended March 31, 2014 and March 31, 2013, and the period from inception (January 1, 2001) to March 31, 2014, and cash flows for the three-month periods ended March 31, 2014 and 2013, and the period from inception (January 1, 2001) to March 31, 2014, have been included. The results of operations for interim periods may not be indicative of the results which may be realized for the full year.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.
Revenue Recognition	'
	Revenue Recognition
	Revenues from software license fees are accounted for in accordance with Accounting Standards Codification (“ASC”) 985-605, “Software Revenue Recognition”. The Company recognizes sales revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured.
	Grant revenue is recognized when earned.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	Based on management's assessment, no new accounting standards, if adopted, would have a material impact on the accompanying financial statements.
Uncertainties	'
	Uncertainties
	The accompanying financial statements have been prepared on a going concern basis. The Company is in the development stage and has insufficient revenue and capital commitments to fund the development of its planned product and to pay operating expenses.
	The Company has realized a cumulative net loss of $20,427,375 for the period from inception (January 1, 2001) to March 31, 2014, and a net loss of $422,504 and $386,343 for the three-months ended March 31, 2014 and 2013, respectively.
	The ability of the Company to continue as a going concern depends on the successful completion of the Company's capital raising efforts to fund the development of its planned products. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Management plans to fund the future operations of the Company with existing cash of $9,446, grants and investor funding.  Under the terms of the Golden State 4.75% Convertible Debenture due on December 31, 2014, Golden State is obligated to submit conversion notices in an amount such that Golden State receives 1% of the outstanding shares of the Company every calendar quarter for a period of one year. In connection with each conversion, Golden State is expected to simultaneously exercise a percentage of warrants equal to the percentage of the principal being converted.  The warrants are exercisable at $381.50 per share.  The number of warrants exercisable is subject to certain beneficial ownership limitations contained in the 4.75% Convertible Debenture (“the Beneficial Ownership Limitations”).  The Beneficial Ownership Limitations prevent Golden State from converting on the 4.75% Convertible Debenture or exercising warrants if such conversion or exercise would cause Golden State’s holdings to exceed 9.99% of the Company’s issued and outstanding common stock.  Subject to the Beneficial Ownership Limitations and provided that Golden State is able to sell the shares under Rule 144, Golden State is required to convert $85.71 of the 4.75% Convertible Debenture and exercise 857 warrants per month.  Based upon the current stock price, the issued and outstanding shares as of March 31, 2014 and ignoring the impact of the Beneficial Ownership Limitations, the Company may receive up to $327,000 per month in funding from Golden State as a result of warrant exercises. Due to the Beneficial Ownership Limitations, the Company received $13,175 in advances from Golden State during the three-month period ended March 31, 2014. Such advances are recorded within warrant exercise advances on the balance sheets when received.
	On July 2, 2013, the Company was awarded a $300,000 grant in the 2013 Oklahoma Applied Research Support competition sponsored by the Oklahoma Center for the Advancement of Science and Technology (“OCAST”). The grant will be used to support the development of the Company’s first Product Platform, which will be the basis for a family of products based on the Company’s CSpace® volumetric 3D display technology (see Note 3).
	Joint Development Agreement with Schott Defense
	As part of the Company’s federal funding strategy, the Company intends to effectively compete by forming interdisciplinary teams with potential strategic partners (large and small), academic and commercial laboratories, and systems integrators providing integrated data visualization solutions. The first of these partnerships was reached in March 2014 when the Company signed a Joint Development Agreement with Schott Defense, a federally focused subsidiary of Schott North America.
	Additionally, the Company is continuing to pursue financing through private offering of debt or common stock.

Debentures_and_Notes_Payable_T

Debentures and Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Debentures and Notes Payable [Abstract]	'
Debentures Payable	'
	Debentures payable consist of the following:
		March 31,		December 31,
		2014		2013
	Senior Convertible Debentures:
	10% Convertible debentures to Directors due June 2014	$	30,000	$	30,000
	10% Convertible debenture due June 2014		29,007		29,007
	4.75% Convertible debenture due December 2014		68,935		69,805
	5.0% Convertible notes due July 2014 (net of $16,482 and $19,115 OID)		115,532		123,590
	15% Convertible bridge notes due 2014 (net of $11,250 and $23,500 OID)		193,750		181,500
	Settlement Agreement 3(a)(10)		-		118,842
	10% Convertible bridge note to Director due December 2014		60,000		60,000
	Total Debentures		497,224		612,744
	Less - Current Maturities		-497,224		-612,744
	Long-term Debentures	$	-	$	-

Common_Stock_and_PaidIn_Capita1

Common Stock and Paid-In Capital (Tables)	3 Months Ended
	Mar. 31, 2014
Common Stock, Including Additional Paid In Capital, Net Of Discount [Abstract]	'
Warrant and Option Activity	'
	The following summary reflects warrant and option activity for the three-month period ended March 31, 2014:
		Attached		Golden State
		Warrants		Warrants		Options
	Outstanding December 31, 2013		10,271,122		19,942		23,030,274
	Granted/purchased		9,500,000		-		-
	Exercised		-		-249		-
	Cancelled		-		-		-
	Outstanding March 31, 2014		19,771,122		19,693		23,030,274

Office_Lease_Tables

Office Lease (Tables)	3 Months Ended
	Mar. 31, 2014
Office Lease [Abstract]	'
Minimum Future Lease Payments	'
	The minimum future lease payments to be paid annually under the three-year non-cancellable amended operating lease for office space are as follows:
	2014		17,000
	2015		13,000
	Total	$	30,000

Uncertainties_and_Use_of_Estim2

Uncertainties and Use of Estimates - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

159 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Jul. 02, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Mar. 31, 2014

Jul. 02, 2013

Mar. 31, 2014

Mar. 31, 2014

Nov. 01, 2007

Mar. 31, 2014

Oklahoma Center for the Advancement of Science and Technology

4.75% Debenture due December 2014

4.75% Debenture due December 2014

4.75% Debenture due December 2014

4.75% Debenture due December 2014

Golden State Debentures

Golden State Debentures

Golden State Debentures

Subsequent Event

Unusual Risk or Uncertainty [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

'

($422,504)

($386,343)

($1,482,049)

($2,101,702)

($2,320,469)

($1,523,737)

($1,566,835)

($3,611,550)

($3,928,996)

($1,469,888)

($592,811)

($617,875)

($51,851)

($267,887)

($259,221)

($20,427,375)

'

'

'

'

'

Convertible Debenture, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.75%

4.75%

'

Receives outstanding shares upon submission of conversion notices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

Warrants exercise, price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$381.50

'

'

Conversion or exercise cause Golden State's holdings to exceed of Company's issued and outstanding common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.99%

'

'

Required amount of Convertible Debenture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.71

'

'

Warrants exercised per month

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

857

'

'

Funds from Golden State result warrant exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

327,000

Grant income

300,000

28,748

0

'

'

'

'

'

'

'

'

'

'

'

'

'

354,136

300,000

9,446

'

'

'

Investor future operations, grants and fund

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated Fair Value Of Warrants

'

$13,175

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$13,175

'

'

'

'

'

Sponsored_Research_Agreement_S1

Sponsored Research Agreement (SRA) Common Stock Subject to Put Right and Call Right - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

159 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Jul. 26, 2013

Dec. 01, 2010

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 01, 2012

Mar. 31, 2014

Nov. 30, 2013

Dec. 01, 2012

Mar. 31, 2014

Apr. 20, 2004

Apr. 15, 2005

Dec. 01, 2010

Oct. 14, 2008

Dec. 01, 2010

Dec. 01, 2010

Nov. 30, 2013

Put Option

Put Option

Put Option

Call Option

Maximum

Pilot Study to Investigate Digital Holography

Investigation of 3-Dimensional Display Technologies

Investigation of 3-Dimensional Display Technologies

3-Dimensional Display Development

3-Dimensional Display Development

3-Dimensional Display Development

University Of Oklahoma

Third Anniversary

Put Option

Stock issued for cash

Stock issued for cash

Post Split

Third Anniversary

Research and Development Arrangement, Contract to Perform for Others [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount paid to University of Oklahoma

'

'

$60,336

$103,604

$5,110,995

'

'

'

'

'

$14,116

$528,843

'

'

$525,481

$40,481

'

Shares issued to University of Oklahoma for Sponsored Research Agreement

650,000

'

'

'

'

'

'

'

'

'

'

'

1,685,714

121,849

'

'

1,807,563

Market Value of shares issued to University of Oklahoma for Sponsored Research Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

290,000

'

'

'

Proceeds from equity

'

'

247,865

209,950

6,495,241

100,000

'

'

970,000

970,000

'

'

'

'

'

'

100,000

Redemption price of rights

'

'

'

'

'

'

$485,000

$50,000

'

'

'

'

'

'

'

'

$50,000

Stockholders equity pre split shares

'

59,000,000

'

'

'

'

'

'

'

'

'

'

'

4,264,707

'

'

'

OCAST_Grant_Additional_Informa

OCAST Grant - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		159 Months Ended
	Jul. 02, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Sep. 01, 2013
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'	'	'	'
Amount earned from grant	$300,000	$28,748	$0	$354,136	'
Grant receivable	'	'	'	'	$300,000

Debentures_and_Notes_Payable_A

Debentures and Notes Payable - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

159 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

Jul. 26, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Jul. 26, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Nov. 03, 2006

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 03, 2006

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Sep. 11, 2012

Oct. 01, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 20, 2012

Jun. 24, 2013

Oct. 01, 2013

Jul. 01, 2014

Oct. 01, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 01, 2012

Jun. 06, 2012

Aug. 01, 2012

Aug. 01, 2012

Jul. 03, 2012

Aug. 24, 2012

Aug. 28, 2012

Dec. 10, 2012

Sep. 11, 2012

Jan. 26, 2013

Dec. 10, 2012

Warrant

Settlement Agreement

Settlement Agreement

10% Convertible debenture due June 2014

10% Convertible debenture due June 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

4.75% Debenture due 2014

5% Convertible Promissory Note

5% Convertible Promissory Note

15% Convertible Bridge Notes

15% Convertible Bridge Notes

15% Convertible Bridge Notes

15% Convertible Bridge Notes

Newton O Connor Turner And Ketchum 10% Convertible Debenture

Victor Keen and Martin Keating 10% convertible debenture

15% Convertible Promissory Note One

Senior Convertible Note

Senior Convertible Note

5% Convertible Bridge Notes

5% Convertible Bridge Notes

5% Convertible Bridge Notes

5% Convertible Bridge Notes

5% Convertible Bridge Notes

5% Convertible Bridge Notes One

5% Convertible Bridge Notes Two

5% Convertible Bridge Notes Two

10% Convertible Bridge Note

10% Convertible Bridge Note

10% Convertible Bridge Note

10% Convertible Bridge Note

10% Convertible Bridge Note

10% Convertible Bridge Note

Convertible Debt

Applied to the exercise of warrants

Golden State

Golden State

Golden State

Golden State

Golden State

Golden State

Golden State

Golden State

Convertible Debt

Convertible Debt

Convertible Debt

Convertible Debt

Victor Keen

Victor Keen

Victor Keen

Convertible Debt

Additional

Applied to the exercise of warrants

Unapplied advances

Debt Conversion [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debt, principal amount

'

'

'

'

'

'

'

$78,789

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

$29,007

'

'

'

$205,000

'

'

'

$415,000

'

$275,000

$140,000

'

'

'

'

'

$60,000

'

Convertible note, conversion price

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.03

$0.01

'

'

'

'

'

'

'

'

$0.15

$0.35

'

'

'

'

'

'

'

Convertible note, conversion description

'

'

'

'

'

'

'

'

'

'

'

'The conversion price for the 4.75% $100,000 convertible debenture is the lesser of (i) $140; or (ii) 80% of the average of the five lowest volume weighted average prices during the twenty (20) trading days prior to the conversion.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In addition to the OID, the 5% Notes provides for a one-time interest charge of 5% to be applied to the principal sum advanced. Pursuant to the terms of 5% Notes, JMJ may, at its election, convert all or a part of the $275,000 note and the $140,000 note into shares of the Company's common stock at a conversion rate equal to the lesser of (i) $0.15 and $0.35, respectively or (ii) 70% of the lowest trade price during the twenty-five trading days prior to JMJ’s election to convert. If the Company repays the 5% Notes on or before ninety days from the date it was issued, the interest rate will be zero percent. If the Company does not repay the 5% Notes on or before ninety days from the date it was issued, a one-time interest charge of 5% shall be applied to the principal. The Company did not repay the 5% Notes within the ninety day period and $8,750 of interest has been accrued. The principal of the 5% Notes is due one year from the date of each of the principal amounts advanced.

'

'

'

'

'

'

'

'

'Upon maturity of the Bridge Notes, the holders of the Bridge Notes may elect to convert all or any portion of the outstanding principal amount of the Bridge Notes into (i) securities sold pursuant to an effective registration statement at the applicable offering price; or (ii) shares of common stock at a conversion price equal to the lesser of 100% of the Volume Weighted Average Price (VWAP), as reported for the 5 trading days prior to (a) the date of issuance of the Bridge Notes, (b) the maturity date of the Bridge Notes, or (c) the first closing date of the securities sold pursuant an effective registration statement.

'

'

'

'

Advances on Debenture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

120,000

150,000

'

'

'

'

'

'

'

'

'

'

'

Convertible debenture, amount converted

'

45,700

54,317

4,911,989

'

'

'

'

'

'

'

'

'

100,000

'

'

3,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

203,700

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible debenture, shares issued

'

'

'

'

'

'

'

'

'

'

'

32,423,426

'

'

'

'

37,651,544

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,854,924

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debenture, conversion price per share

'

'

'

'

'

'

'

'

'

'

'

$381.50

'

'

'

'

'

'

'

$870

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

Debenture, prepay portion in percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock, issued

'

'

'

'

'

'

6,810,811

'

'

'

'

'

'

'

'

'

'

'

28,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock, issued, price per share

'

'

'

'

'

0.0055

'

'

'

'

'

'

'

'

'

'

381.5

'

381.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00239

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

148,706

'

'

50,140

'

1,103

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advance against future exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

671,810

'

'

'

13,175

420,740

185,671

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Original issue discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,750

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

Original issue discount collected

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,975

32,205

14,000

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issuable under registration statement

'

'

'

'

'

'

9,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,750,000

'

'

'

'

'

'

Registration statement filing period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'120 days

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

73,000

'

'

'

'

Placement Agent Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,682

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debenture, interest rate

'

'

'

'

'

'

'

'

'

'

4.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

'

15.00%

'

'

'

'

'

'

'

'

'

'

15.00%

10.00%

'

'

15.00%

Debt instrument aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

438,000

'

'

60,000

'

'

Proceeds from notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

174,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

365,000

'

'

'

'

Conversion of convertible debentures into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,667

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible debentures into common stock, shares

'

'

'

'

'

'

'

'

'

'

'

249

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, shares, conversion of units

'

'

'

'

'

'

'

53,720,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts payable

197,631

'

'

'

'

'

197,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period shares other

650,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion rate to closing bid price

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion closing bid price

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Volume Weighted Average Price

'

'

'

'

'

'

'

'

'

'

0.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated Fair Value Of Warrants

'

13,175

'

13,175

'

2,130

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

173.64%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

1.39%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining balance paid in cash

'

'

'

'

'

'

190,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debt net

'

$497,224

'

$497,224

$612,744

'

'

'

$29,007

$29,007

'

$68,935

$69,805

'

'

'

'

'

'

'

'

'

'

$16,482

$19,115

'

'

$11,250

$23,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debentures_and_Notes_Payable_D

Debentures and Notes Payable (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	$497,224	$612,744
Less - Current Maturities	-497,224	-612,744
Long-term Debentures	0	0
10% convertible debentures from Directors due June 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	30,000	30,000
10% Convertible debenture due June 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	29,007	29,007
4.75% Convertible debenture due December 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	68,935	69,805
5.0% Convertible notes due July 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	115,532	123,590
Settlement Agreement 3(a)(10)	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	0	118,842
15% Convertible bridge notes due 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	193,750	181,500
10% Convertible bridge note to Director due December 2014	'	'
Debt Instrument [Line Items]	'	'
Senior Convertible Debentures	$60,000	$60,000

Common_Stock_and_PaidIn_Capita2

Common Stock and Paid-In Capital - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Jan. 23, 2014

Dec. 11, 2013

Dec. 09, 2013

Apr. 11, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2007

Dec. 31, 2006

Dec. 11, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Mar. 31, 2014

Mar. 31, 2014

Jan. 23, 2014

Mar. 16, 2012

Mar. 31, 2014

Mar. 16, 2012

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Warrant

Warrant

Warrant

Common Stock

Common Stock

Series A Convertible Preferred Stock

Group Two

Group Two

Group Three

Group Three

Group Six

Group Six

Group Six

Group Seven

Group Seven

Group Eight

Group Eight

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Stock issued for services

Consulting Services

Common Stock And Options Issued

Mark Willner

George Melnik

George Melnik

George Melnik

George Melnik

George Melnik

George Melnik

George Melnik

Expire on May 22, 2014

Expire on June 1, 2015

Expire on December 31,2014

17-Jan-18

31-Mar-19

31-Dec-17

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Employee Stock Option

Employee Stock Option

Employee Stock Option

Employee Stock Option

Employee Stock Option

Conversion of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

9,750,000

'

'

'

'

'

'

'

'

'

'

125,098

'

96,024

'

19,942

'

9,500,000

300,000

'

9,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants outstanding, exercise price

'

'

'

'

'

'

'

'

0.0055

'

'

'

'

3.15

'

3.15

'

381.5

'

'

0.0032

'

0.0055

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued for consulting services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,376,344

25,892,479

2,248,640

30,072,595

97,684,416

68,506,130

4,598,973

817,727

4,700,000

5,850,000

24,036,000

15,347,000

3,077,000

2,681,310

'

9,376,344

'

'

'

'

'

'

'

'

Stock issued for consulting services, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$45,000

$295,350

$246,100

$355,205

$232,886

$538,354

$313,800

$155,426

$206,537

$26,371

$76,489

$15,347

$129,448

$188,131

$1,875

$5,178

$450

$6,015

$19,538

$13,701

$920

$164

$940

$1,170

$4,807

$15,347

$3,077

$2,681

$45,000

'

'

'

'

'

'

'

'

'

Common stock issued to consultants for previous services provided

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,317,073

'

'

'

'

'

'

'

'

'

Reduction in accounts payable liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

Employment agreement, terms effective period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'1 year

'

'

'

'

'

Annual base salary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

144,000

'

'

'

'

'

'

Stock options granted, term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,571

'

'

'

'

'

'

Stock option plan, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.35

'

'

'

'

'

'

Additional Stock option plan, shares granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,571

28,571

28,571

28,571

Estimated fair value of options

'

'

'

'

'

'

34,926

'

27,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,420

9,420

9,420

9,420

Expected dividend yield

'

'

'

'

'

'

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Expected volatility

'

'

'

'

'

'

180.00%

'

178.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

163.00%

'

'

'

'

Risk-free interest

'

'

'

'

'

'

1.64%

'

1.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.87%

'

'

'

'

Expected life of option

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Employment agreement, termination period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'60 years

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, gross

'

'

'

10,000,000

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum purchase of restricted common shares

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum purchase of restricted common shares purchase price per share

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from options agreements

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for repurchase of private placement

'

195,000

195,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock for gross proceed

'

'

195,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase of common stock

'

'

50

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of private placement

'

'

195,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

'

500,000

500,000

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share

'

'

'

'

$0.00

$0.00

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Conversion Of Convertible Securities

190,000

'

'

'

'

'

'

'

'

8,585,956

16,489,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

190,000

'

'

'

'

'

'

'

Conversion Price Of Stock

'

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock outstanding percentage

'

'

'

'

4.99%

9.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Debt

$385,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$385,000

'

'

'

'

'

'

'

Warrant_and_Option_Activity_De

Warrant and Option Activity (Detail)	3 Months Ended
	Mar. 31, 2014
Attached Warrants	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding beginning of period	10,271,122
Granted/purchased	9,500,000
Exercised	0
Cancelled	0
Outstanding at end of period	19,771,122
Golden State Warrants	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding beginning of period	19,942
Granted/purchased	0
Exercised	-249
Cancelled	0
Outstanding at end of period	19,693
Options	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Outstanding beginning of period	23,030,274
Granted/purchased	0
Exercised	0
Cancelled	0
Outstanding at end of period	23,030,274

Incentive_Stock_Plan_Additiona

Incentive Stock Plan - Additional Information (Detail)	12 Months Ended				12 Months Ended			3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Apr. 30, 2012	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2014
	2012 Equity Incentive Plan	2012 Equity Incentive Plan	2012 Equity Incentive Plan	2012 Equity Incentive Plan	2013 Equity Incentive Plan	2013 Equity Incentive Plan	2013 Equity Incentive Plan	2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Incentive stock plan, authorized	'	'	'	5,000,000	'	'	20,000,000	50,000,000
Incentive stock plan, issued	2,827,537	2,172,463	'	'	20,000,000	'	'	12,046,093
Incentive stock plan, shares available for issuance	'	'	0	'	'	0	'	37,563,907

Office_Lease_Additional_Inform

Office Lease - Additional Information (Detail)	3 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 08, 2011	Jul. 24, 2012
		First Amendment	Second Amendment
Lease agreement signed date	24-Apr-08	'	'
Lease agreement commencement date	1-Jun-08	'	'
Lease expiration date	1-Jun-11	'	'
Extended lease expiration date	'	31-May-12	31-Jul-15

Minimum_Future_Lease_Payments_

Minimum Future Lease Payments (Detail) (USD $)	Mar. 31, 2014
Future Minimum Payments Under Non-Cancelable Operating Leases With Initial Terms Of One-Year Or More [Line Items]	'
2014	$17,000
2015	13,000
Total	$30,000

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (Newton, O'Connor, Turner & Ketchum, a professional corporation ("NOTK"), USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Newton, O'Connor, Turner & Ketchum, a professional corporation ("NOTK")	'	'
Related Party Transaction [Line Items]	'	'
Legal fees incurred to Newton	$1,940	$8,203

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

159 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

Jul. 26, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2005

Dec. 31, 2004

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Golden Gate Debenture

4.75% Convertible Debenture

Settlement Agreement

Consulting Services

Jmj Converted

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants exercised

'

'

'

'

'

'

'

'

'

243

'

'

'

Warrants exercise price per share

'

'

'

'

'

'

'

'

$381.50

$381.50

'

'

'

Advance payment for future exercise of warrants

'

'

'

'

'

'

'

'

'

$46,325

'

'

'

Expense recognized for common stock shares issued for services

'

45,000

0

'

'

'

'

2,824,444

'

'

'

9,267

'

Stock issued during period shares other

650,000

'

'

'

'

'

'

'

'

'

'

4,496,450

'

Stock Issued During Period Value Stock Warrants Exercised

'

'

'

518,000

382,590

174,000

61,000

'

'

92,650

'

'

'

Convertible note, conversion price

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

$0.00

Conversion Of Convertible Debentures Into Common Stock Value

'

'

'

'

'

'

'

'

'

$850

'

'

$22,050

Conversion Of Convertible Debentures Into Common Stock Shares

'

'

'

'

'

'

'

'

'

7,982,953

'

'

9,000,000